Zobrazeno 1 - 10
of 86
pro vyhledávání: '"Sean A. Evans"'
Autor:
Sean T Evans, Yash Jani, Caroline S Jansen, Ahmet Yildirim, Ecem Kalemoglu, Mehmet Asim Bilen
Publikováno v:
Cancer Biology & Therapy, Vol 25, Iss 1 (2024)
The introduction of novel immunotherapies has significantly transformed the treatment landscape of genitourinary (GU) cancers, even becoming the standard of care in some settings. One such type of immunotherapy, immune checkpoint inhibitors (ICIs) li
Externí odkaz:
https://doaj.org/article/082b3f99543f4a1ea7b9fa6358747071
Publikováno v:
Journal of Vascular Anomalies, Vol 4, Iss 4, p e075 (2023)
Objective:. To determine baseline quality of life characteristics in patients with low-flow head and neck vascular malformations. Study Design:. Retrospective review of prospectively collected data. Setting:. Tertiary Pediatric Hospital. Methods:. Pa
Externí odkaz:
https://doaj.org/article/8f5fe832a4084910abc2aeb6fed0d3f2
Autor:
Caroline S. Jansen, Yujin Choi, Sean T. Evans, Rachel Greenwald, Joseph A. Behnke, Caitlin Hartman, Haydn Kissick, Lara R. Harik, Mehmet Asim Bilen
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Extrarenal clear cell renal cell carcinoma (eccRCC) is a rare type of RCC that arises in areas other than the kidney. Given its rarity, consensus guidelines for optimal treatment of eccRCC have not been established, and the literature is lacking any
Externí odkaz:
https://doaj.org/article/b957ea377e384a84a09b869d05f9bc07
Autor:
Dylan J. Martini, T. Anders Olsen, Subir Goyal, Yuan Liu, Sean T. Evans, Emilie Elise Hitron, Greta Anne Russler, Lauren Yantorni, Sarah Caulfield, Jacqueline T. Brown, Jamie M. Goldman, Bassel Nazha, Bradley C. Carthon, Wayne B. Harris, Omer Kucuk, Viraj A Master, Mehmet Asim Bilen
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Pp 52-57 (2022)
Introduction: There are three combination immune checkpoint inhibitor (ICI)–based regimens in the first-line setting for metastatic renal cell carcinoma (mRCC). Currently, there is limited real-world data for clinical outcomes and toxicity in mRCC
Externí odkaz:
https://doaj.org/article/3b523ccfbd2e4ae9ba07ac843f39a4e8
Autor:
Maria I. Ventura, Allen Azizian, Sean E. Evans, Susan Velasquez, Juan Carlos Arguello, Katherine Warburton
Publikováno v:
Public Health in Practice, Vol 4, Iss , Pp 100307- (2022)
Objectives: COVID-19 vaccinations are highly efficacious in preventing severe illness that can lead to hospitalizations and death, but incidents of vaccine breakthrough (VBT) infections persist. We examined VBT infections within a congregate setting
Externí odkaz:
https://doaj.org/article/719698d7281348e49f23a7379c4b818f
Publikováno v:
Journal of Medical Case Reports, Vol 15, Iss 1, Pp 1-6 (2021)
Abstract Background Combination regimens that include immune checkpoint (ICI) and vascular endothelial growth factor (VEGF) inhibition have opened the door to new treatment opportunities for patients with metastatic renal cell carcinoma (mRCC). While
Externí odkaz:
https://doaj.org/article/fb1cc12f7d754fb58abddcaa113190e6
Autor:
Dylan J. Martini, Caroline S. Jansen, Lara R. Harik, Sean T. Evans, T. Anders Olsen, Viraj A. Master, Haydn T. Kissick, Mehmet Asim Bilen
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Translocation-associated renal cell carcinoma (tRCC) is a rare, aggressive malignancy that primarily affects children and young adults. There is no clear consensus on the most effective treatment for tRCC and there are no biomarkers of response to tr
Externí odkaz:
https://doaj.org/article/da6ce88eaca443b4b36d698e6a2035ef
Autor:
Dylan J. Martini, T. Anders Olsen, Subir Goyal, Yuan Liu, Sean T. Evans, Benjamin Magod, Jacqueline T. Brown, Lauren Yantorni, Greta Anne Russler, Sarah Caulfield, Jamie M. Goldman, Bassel Nazha, Haydn T. Kissick, Wayne B. Harris, Omer Kucuk, Bradley C. Carthon, Viraj A. Master, Mehmet Asim Bilen
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundImmune checkpoint inhibitors (ICI) have revolutionized the treatment of metastatic renal cell carcinoma (mRCC). Biomarkers for mRCC patients treated with ICI are limited, and body composition is underutilized in mRCC. We investigated the as
Externí odkaz:
https://doaj.org/article/9162907753ca46b98f276622972a2ce3
Autor:
T. Anders Olsen, Dylan J. Martini, Subir Goyal, Yuan Liu, Sean T. Evans, Benjamin Magod, Jacqueline T. Brown, Lauren Yantorni, Greta Anne Russler, Sarah Caulfield, Jamie M. Goldman, Wayne B. Harris, Omer Kucuk, Bradley C. Carthon, Viraj A. Master, Bassel Nazha, Mehmet Asim Bilen
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundImmune-checkpoint-inhibitors (ICIs) have become the cornerstone of metastatic renal-cell-carcinoma (mRCC) therapy. However, data are limited regarding clinical outcomes by race. In this study, we compared the real-world outcomes between Afr
Externí odkaz:
https://doaj.org/article/3aa9b41eb0064fb78cd9cab2b089a0c5
